{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:23Z","timestamp":1786122083967,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: In this study, we investigate clinical and pathological parameters that may be associated with EGFR mutations. We aimed to contribute to the literature by understanding other potential clinical and pathological factors that could be useful in predicting patients with a high probability of responding to immunotherapy and by investigating the relationship between PD-L1 expression and driver mutations. Materials and Methods: This study included 141 biopsy specimens and 97 resection specimens diagnosed with NSCLC between 2015 and 2022. Statistical analyses were performed using the IBM SPSS Version 29.0 program. Results: In our study, consistent with the literature, a significant association was found between the presence of EGFR mutations and female sex and non-smoking status (p &lt; 0.001). No statistically significant association was found between PD-L1 expression status and individual driver alterations, including EGFR, BRAF, ALK, and ROS1 (p &gt; 0.05 for all). The association between PD-L1 expression status and non-adenocarcinoma histological types, particularly squamous cell carcinoma (10.1%) and NSCLC-NOS (14.5%), was statistically significant; PD-L1 positivity was higher in non-adenocarcinoma tumors (70.6%) compared to adenocarcinomas (43.3%; p = 0.009). Conclusions:  In groups of patients with early-stage and locally advanced disease, the mean overall survival time was significantly lower for those with ALK translocations, which contrasts with the existing literature, and this finding was determined to be an independent poor prognostic factor (HR: 8.6, 95% CI: 1.9\u201338, p = 0.004).<\/jats:p>","DOI":"10.3390\/medicina62081521","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:01:36Z","timestamp":1786089696000},"page":"1521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relationship Between EGFR Mutation Status and Clinicopathological Parameters in Non-Small Cell Lung Carcinomas and Correlation of PD-L1 Expression"],"prefix":"10.3390","volume":"62","author":[{"given":"Sumru","family":"Cagaptay","sequence":"first","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Aysal","family":"Agalar","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-3926","authenticated-orcid":false,"given":"Kubra","family":"Canaslan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Gurel","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Timur","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Cagnur","family":"Ulukus","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-4832","authenticated-orcid":false,"given":"Fatma Ilknur","family":"Ulugun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Karacam","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"Oztop","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung Cancer 2020: Epidemiology, Etiology, and Prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.coph.2013.03.010","article-title":"Novel therapeutic targets in non-small cell lung cancer","volume":"13","author":"Alamgeer","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Canaslan, K., Eken, E., Bilici, M., Balc\u0131o\u011flu, F.M., \u00d6zt\u00fcrk, B., \u00c7akmak, M., Bal, \u00d6., Turhan, G., \u00d6zdemir, F., and Arvas, H. (2025). Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in T\u00fcrkiye. Genes, 16.","DOI":"10.3390\/genes16121446"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1556-0864(15)31573-2","article-title":"Clinicopathologic Characteristics of the EGFR Gene Mutation in Non\u2013small Cell Lung Cancer","volume":"1","author":"Tsao","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e18075","DOI":"10.1200\/jco.2011.29.15_suppl.e18075","article-title":"The relationship between common EGFR, b-raf, k-ras mutations, and prognosis in advanced-stage NSCLC with response to the treatment","volume":"29","author":"Dogan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.21873\/cgp.20216","article-title":"Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer","volume":"17","author":"Chevallier","year":"2020","journal-title":"Cancer Genom. Proteom."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_11","first-page":"51","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","article-title":"Anti-Tumour Treatment A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: The future is now","volume":"54","author":"Bellmunt","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1758835918763493","DOI":"10.1177\/1758835918763493","article-title":"PD-L1 expression testing in non-small cell lung cancer","volume":"10","author":"Reyes","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","article-title":"PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee","volume":"15","author":"Lantuejoul","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer","volume":"25","author":"Azuma","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10255","DOI":"10.1038\/s41598-017-10925-7","article-title":"PD-L1 expression in lung cancer and its correlation with driver mutations: A meta-analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_19","unstructured":"Kilinc, O., Turker, H., Topcu, S., Sevinc, C., Capan, N., Umut, S., Yilmaz, U., Elbek, O., Okumus, G., and Metintas, M. (2020). Turkish Thoracic Society Lung Cancer Diagnosis and Treatment Consensus Report, Turkish Thoracic Society Publications. (In Turkish)."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","unstructured":"IASLC (2024, March 12). Atlas of Molecular Testing for Targeted Therapy in Lung Cancer|IASLC. Available online: https:\/\/www.iaslc.org\/iaslc-atlas-molecular-testing-targeted-therapy-lung-cancer."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jjco\/hyt049","article-title":"Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: Combined analysis of two phase III trials (NEJ 002 and WJTOG 3405)","volume":"43","author":"Akamatsu","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/JTO.0b013e3182828fb8","article-title":"Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC\/ATS\/ERS lung adenocarcinoma classification in stage III (N2) patients","volume":"8","author":"Russell","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.18632\/oncotarget.12540","article-title":"Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma","volume":"8","author":"Luo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brenner, D.R., McLaughlin, J.R., and Hung, R.J. (2011). Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017479"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jjco\/hyi228","article-title":"A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma","volume":"36","author":"Haneda","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/modpathol.2009.154","article-title":"Clinicopathological predictors of EGFR\/KRAS mutational status in primary lung adenocarcinomas","volume":"23","author":"Dacic","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/JTO.0b013e3182381515","article-title":"High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: Correlation with histologic subtypes, EGFR\/TTF-1 expressions, and clinical features","volume":"7","author":"Sun","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/cytojournal.cytojournal_45_17","article-title":"Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma","volume":"15","author":"Sharma","year":"2018","journal-title":"Cytojournal"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10555-010-9205-8","article-title":"EGFR mutations and the terminal respiratory unit","volume":"29","author":"Yatabe","year":"2010","journal-title":"Cancer Metastasis Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","unstructured":"Aky\u00fcrek, N., Nart, D., \u00d6z, B., and Dizbay Sak, S. (2021). K\u00fc\u00e7\u00fck H\u00fccreli D\u0131\u015f\u0131 Akci\u011fer Kanseri \u0130\u00e7in Molek\u00fcler Testler Tan\u0131 Rehberi 2021, Patoloji Dernekleri Federasyonu. Available online: https:\/\/turkpath.org.tr\/files\/pdf\/K%C3%BC%C3%A7%C3%BCk%20H%C3%BCcreli%20D%C4%B1%C5%9F%C4%B1%20Akci%C4%9Fer%20Kanseri%20%C4%B0%C3%A7in%20Molek%C3%BCler%20Testler%20Tan%C4%B1%20Rehberi%202021.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/ejcts\/ezaa172","article-title":"Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: A systematic review and meta-analysis","volume":"58","author":"Chen","year":"2020","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155013","DOI":"10.1016\/j.prp.2023.155013","article-title":"Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective","volume":"253","author":"Aggarwal","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lungcan.2021.09.011","article-title":"Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma","volume":"161","author":"Takamochi","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.31557\/APJCP.2022.23.1.131","article-title":"Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype","volume":"23","author":"Pandey","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jtho.2022.06.001","article-title":"Lung Cancer in Turkey","volume":"17","author":"Yumuk","year":"2022","journal-title":"J. Thorac. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:38:19Z","timestamp":1786091899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081521"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081521","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}